Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 840-202-3 | CAS number: 2101947-22-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- The study was conducted between 18 January 2017 and 24 May 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Well conducted and well described study in accordance with GLP and OECD guideline 473 without any deviation
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- 2-ethyl-N-(3-methoxyphenyl)-N-methylbutanamide
- Cas Number:
- 2101947-22-0
- Molecular formula:
- C14H21NO2
- IUPAC Name:
- 2-ethyl-N-(3-methoxyphenyl)-N-methylbutanamide
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- Identification: FRET 15-0735
Chemical Name: 2-ETHYL-N-(3-METHOXYPHENYL)-N-METHYL-BUTANAMIDE
Physical state/Appearance: Extremely pale yellow liquid
Storage Conditions: Approximately 4 ºC in the dark
Method
Species / strain
- Species / strain / cell type:
- lymphocytes: cultures prepared from whole blood
- Details on mammalian cell type (if applicable):
- For each experiment, sufficient whole blood was drawn from the peripheral circulation of a non smoking volunteer (aged 18-35) who had been previously screened for suitability. The volunteer had not knowingly been exposed to high levels of radiation or hazardous chemicals and had not knowingly recently suffered from a viral infection. Based on over 20 years in house data for cell cycle times for lymphocytes using BrdU (bromodeoxyuridine) incorporation to assess the number of first, second and third division metaphase cells to calculate the average generation time (AGT) for human lymphocytes it is considered to be approximately 16 hours. Therefore using this average the in-house exposure time for the experiments for 1.5 x AGT is 24 hours.
The details of the donors used are:
Preliminary Toxicity Test: male, aged 25 years
Main Experiment (4(20)-hour without S9 and 24-hour): female, aged 33 years
Main Experiment (4(20)-hour with S9): female, aged 27 years - Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- induced rat liver homogenate metabolizing system (S9), at a 2% final concentration
- Test concentrations with justification for top dose:
- Range-finder experiment: 7.81 to 2000 µg/mL (with and without S-9)
Main study:
4-hour exposure to the test item without S9-mix, followed by 20-hour culture in treatment-free media prior to cell harvest. The dose range of test item used was 31.25, 62.5, 125, 250, 312.5, 375 and 500 µg/mL.
4-hour exposure to the test item with S9-mix (2%), followed by 20-hour culture in treatment-free media prior to cell harvest. The dose range of test item used was 62.5, 125, 250, 312.5, 375, 437.5 µg/mL.
24-hour continuous exposure to the test item without S9-mix prior to cell harvest. The dose range of test item used was 7.81, 15.63, 31.25, 62.5, 125, 187.5 and 250 µg/mL.
The 4(20)-hour exposure group in the presence of S9 was initially performed with the dose range:- 31.25, 62.5, 125, 187.5, 250, 312.5 and 500 µg/mL. However, the toxicity curve was very steep and optimum toxicity was not achieved and therefore this exposure group was repeated with the revised dose range stated above. - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
Controlsopen allclose all
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 0.4 µg/mL for 4-hour exposure and 0.1 µg/mL for 24-hour exposure
- Positive control substance:
- mitomycin C
- Remarks:
- without metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 2 µg/mL for 4-hour exposure
- Positive control substance:
- cyclophosphamide
- Remarks:
- with metabolic activation
- Details on test system and experimental conditions:
- PREPARATION OF CULTURES: Cells (whole blood cultures) were grown in Eagle's minimal essential medium with HEPES buffer (MEM), supplemented “in-house” with L-glutamine, penicillin/streptomycin, amphotericin B and 10 % foetal bovine serum (FBS), at approximately 37 ºC with 5 % CO2 in humidified air. The lymphocytes of fresh heparinized whole blood were stimulated to divide by the addition of phytohaemagglutinin (PHA).
METHOD OF APPLICATION: In medium
DURATION
- Preincubation period: approximately 48 hours incubation at approximately 37 ºC with 5% CO2 in humidified air
- Exposure duration:
Three exposure groups were used:
i) 4-hour exposure to the test item without S9-mix, followed by a 20-hour recovery period in treatment-free media, 4(20)-hour exposure.
ii) 4-hour exposure to the test item with S9-mix (2%), followed by a 20-hour recovery period in treatment-free media, 4(20)-hour exposure.
iii) 24-hour continuous exposure to the test item without S9-mix.
- Fixation time (start of exposure up to fixation or harvest of cells): 24hrs
SPINDLE INHIBITOR (cytogenetic assays): Colcemid 0.1 µg/mL 2.5 hours before the required harvest time.
STAIN (for cytogenetic assays): 5% Giemsa for 5 minutes
NUMBER OF REPLICATIONS: duplicate
METHODS OF SLIDE PREPARATION AND STAINING TECHNIQUE USED:
After incubation with demecolcine, the cells were centrifuged, the culture medium was drawn off and discarded, and the cells re-suspended in 0.075M hypotonic KCl. After approximately fourteen minutes (including centrifugation), most of the hypotonic solution was drawn off and discarded. The cells were re-suspended and then fixed by dropping the KCl cell suspension into fresh methanol/glacial acetic acid (3:1 v/v). The fixative was changed at least three times and the cells stored at approximately 4 ºC to ensure complete fixation prior to slide preparation. The lymphocytes were re-suspended in several mL of fresh fixative before centrifugation and re-suspension in a small amount of fixative. Several drops of this suspension were dropped onto clean, wet microscope slides and left to air dry. Each slide was permanently labeled with the appropriate identification data. When the slides were dry they were stained in 5% Giemsa for 5 minutes, rinsed, dried and a cover slip applied using mounting medium.
NUMBER OF CELLS EVALUATED: A total of 2000 lymphocyte cell nuclei were counted and the number of cells in metaphase recorded and expressed as the mitotic index and as a percentage of the vehicle control value.
NUMBER OF METAPHASE SPREADS ANALYSED PER DOSE (if in vitro cytogenicity study in mammalian cells): Where possible, 300 consecutive well-spread metaphases from each concentration were counted (150 per duplicate), where there were at least 15 cells with aberrations (excluding gaps), slide evaluation was terminated. If the cell had 44-48 chromosomes, any gaps, breaks or rearrangements were noted according to the simplified system of Savage (1976) recommended in the 1983 UKEMS guidelines for mutagenicity testing and the ISCN (1985). Cells with chromosome aberrations were reviewed as necessary by a senior cytogeneticist prior to decoding the slides.
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index
OTHER EXAMINATIONS:
- Determination of polyploidy: cells with 69 chromosomes or more were scored as polyploid cells and the incidence of polyploid cells (%) (including the incidence of cells with endoreduplicated chromosomes) reported - Evaluation criteria:
- The following criteria were used to determine a valid assay:
- The frequency of cells with structural chromosome aberrations (excluding gaps) in the vehicle control cultures was within the laboratory historical control data range.
- All the positive control chemicals induced a positive response (p≤0.01) and demonstrated the validity of the experiment and the integrity of the S9-mix.
- The study was performed using all three exposure conditions using a top concentration which meets the requirements of the current testing guideline.
- The required number of cells and concentrations were analyzed.
Criteria for determining the Study Conclusion
Providing that all of the acceptability criteria are fulfilled, a test item can be considered to be clearly negative if, in any of the experimental conditions examined:
1) The number of cells with structural aberrations in all evaluated dose groups should be within the range of the laboratory historical control data.
2) No toxicologically or statistically significant increase of the number of cells with structural chromosome aberrations is observed following statistical analysis.
3) There is no concentration-related increase at any dose level
A test item can be classified as genotoxic if:
1) The number of cells with structural chromosome aberrations is outside the range of the laboratory historical control data.
2) At least one concentration exhibits a statistically significant increase in the number of cells with structural chromosome aberrations compared to the concurrent negative control.
3) The observed increase in the frequency of cells with structural aberrations is considered to be dose-related
When all of the above criteria are met, the test item can be considered able to induce chromosomal aberrations in human lymphocytes. - Statistics:
- The frequency of cells with aberrations excluding gaps and the frequency of polyploid cells was compared, where necessary, with the concurrent vehicle control value using Fisher's Exact test.
A toxicologically significant response is recorded when the p value calculated from the statistical analysis of the frequency of cells with aberrations excluding gaps is less than 0.05 when compared to its concurrent control and there is a dose-related increase in the frequency of cells with aberrations which is reproducible. Incidences where marked statistically significant increases are observed only with gap-type aberrations will be assessed on a case by case basis.
Results and discussion
Test results
- Species / strain:
- lymphocytes: human
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- Preliminary Toxicity Test
The dose range for the Preliminary Toxicity Test was 7.81, 15.63, 31.25, 62.5, 125, 250, 500, 1000 and 2000 µg/mL. The maximum dose was the maximum recommended dose level.
A precipitate of the test item was observed in the parallel blood-free cultures at the end of the exposure, at 2000 µg/mL, in the 4(20)-hour exposure groups and at and above 500 µg/mL in the continuous exposure group.
Hemolysis was observed following exposure to the test item at and above 1000 µg/mL and 500 µg/mL in the 4(20)-hour exposure groups in the absence and presence of S9, respectively and at and above 250 µg/mL in the 24-hour exposure group. Hemolysis is an indication of a toxic response to the erythrocytes and not indicative of any genotoxic response to the lymphocytes.
Microscopic assessment of the slides prepared from the exposed cultures showed that metaphase cells were present up to 250 µg/mL in the 4(20)-hour exposures in the presence and absence of metabolic activation (S9). The maximum dose with metaphases present in the 24 hour continuous exposure was 125 µg/mL. The test item induced marked evidence of toxicity in all three of the exposure groups.
The selection of the maximum dose level for the Main Experiment was based on toxicity and was 500 µg/mL for the 4(20)-hour exposure groups and was 250 µg/mL for the continuous exposure group.
Chromosome Aberration Test – Main Experiment
The qualitative assessment of the slides determined that the toxicity was less than that observed in the Preliminary Toxicity Test in the 4(20)-hour exposure in the absence of S9 and there were metaphases suitable for scoring present up to 500 µg/mL. In the 4(20)-hour exposure in the presence of S9 and in the 24-hour exposure the toxicity was similar to that seen in the Preliminary Toxicity Test and there were metaphases suitable for scoring up to 437.5 µg/mL and 125 µg/mL, respectively.
Precipitate observations were made at the end of exposure and no precipitate was observed in any of the three exposure groups. Haemolysis was observed at the end of exposure at and above 375 µg/mL in the presence of S9 and at 250 µg/ml in the 24-hour exposure.group.
They confirm the qualitative observations in that a dose-related inhibition of mitotic index was observed. In the 4(20)-hour exposure group in the absence of S9, 56% mitotic inhibition was achieved at 500 µg/mL. In the presence of S9, the toxicity plateaued at 250, 312.5 and 375 µg/mL with 50%, 38% and 63% mitotic inhibition, respectively. The 24-hour exposure group achieved marginally greater than optimum toxicity with 67% mitotic inhibition at 62.5 µg/mL.
The maximum dose level selected for metaphase analysis was based on toxicity and was 500 µg/mL and 375 µg/mL for the 4(20)-hour exposures in the absence and presence of S9, respectively and was 62.5 µg/mL for the 24-hour exposure group.
The assay was considered valid as it met all of the following criteria:
The frequency of cells with chromosome aberrations (excluding gaps) in the vehicle control cultures were within the current historical control data range.
All the positive control chemicals induced a demonstrable positive response (p≤0.01) and confirmed the validity and sensitivity of the assay and the integrity of the S9-mix.
The study was performed using all three exposure conditions using a top concentration which meets the requirements of the current testing guideline.
The required number of cells and concentrations were analyzed.
The test item did not induce any statistically significant increases in the frequency of cells with aberrations either in the absence or presence of metabolic activation.
The test item did not induce a significant increase in the numbers of polyploid cells at any dose level in any of the three exposure groups.
Any other information on results incl. tables
The dose levels of the controls and the test item are given in the table below:
Exposure Group |
Final concentration of FRET 15-0735 (µg/mL) |
4(20)-hour without S9 |
0*, 31.25, 62.5, 125, 250*, 312.5*, 375*, 500*, MMC0.4* |
4(20)-hour with S9 (2%) |
0*, 62.5, 125*, 250*, 312.5*, 375, 437.5, 500, CP2* |
24-hour without S9 |
0*, 7.81*, 15.63*, 31.25*, 62.5*, 125, 187.5, 250, MMC 0.1* |
* = Dose levels selected for metaphase analysis
MMC = Mitomycin C
CP = Cyclophosphamide
Mitotic Index - Preliminary Toxicity Test
Dose Level (µg/mL) |
4(20)-Hour Without S9 |
4(20)-Hour With S9 |
24-Hour Without S9 |
|||
Mitotic Index |
% of Control |
Mitotic Index |
% of Control |
Mitotic Index |
% of Control |
|
0 |
7.15 |
100 |
8.10 |
100 |
4.70 |
100 |
7.81 |
- |
- |
- |
- |
- |
- |
15.63 |
- |
- |
- |
- |
4.90 |
104 |
31.25 |
5.80 |
81 |
6.05 |
75 |
3.35 |
71 |
62.5 |
7.50 |
105 |
7.20 |
89 |
2.30 |
49 |
125 |
6.45 |
90 |
6.95 |
86 |
2.30 |
49 |
250 |
6.60 |
92 |
4.05 |
50 |
NM H |
NM |
500 |
NM |
NM |
NM |
NM |
NM H P |
NM |
1000 |
NM H |
NM |
NM H |
NM |
NM H P |
NM |
2000 |
NM H P |
NM |
NM H P |
NM |
NM H P |
NM |
- = Not assessed for mitotic index
NM = No metaphases or insufficient metaphases suitable for scoring
P = Precipitate observed at end of exposure period in blood-free cultures
H = Hemolysis observed at the end of exposure in blood cultures
Mitotic Index – Main Experiment (24-hour Exposure Group)
Dose Level (µg/mL) |
24-Hour Without S9 |
|||
A |
B |
Mean |
% of Control |
|
0 |
6.60 |
6.40 |
6.50 |
100 |
7.81 |
5.45 |
5.60 |
5.53 |
85 |
15.63 |
4.60 |
3.95 |
4.28 |
66 |
31.25 |
6.50 |
4.30 |
5.40 |
83 |
62.5 |
2.45 |
1.80 |
2.13 |
33 |
125 |
1.30 |
1.50 |
1.40 |
22 |
187.5 |
NM |
NM |
NM |
NM |
250 |
NM H |
NM H |
NM |
NM |
MMC 0.1 |
3.10 |
2.50 |
2.80 |
43 |
MMC =Mitomycin C
- =Not assessed for mitotic index
NM =No metaphases suitable for scoring
H =Hemolysis
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results:
negative
Under the test conditions, FRET 15-0735 is not considered as clastogenic in human lymphocytes according to the criteria of the Annex VI to the Directive 67/548/EEC and CLP Regulation (EC) N° (1272-2008). - Executive summary:
In an in vitro chromosome aberration test performed according to OECD guideline 473 and in compliance with GLP, human primary lymphocyte cultures were exposed to FRET 15-0735 in DMSO at concentration range of 7.81 to 2000 µg/mL., for 4 + 20 h (treatment + recovery) with metabolic activation (induced rat liver homogenate metabolizing system (S9), at a 2% final concentration), and for 4 + 20 h or 24 + 0 h (treatment + recovery) without metabolic activation for a preliminary cytotoxicity test (Lloyd 2010). In the main test, two experiments were performed at concentrations up to 500 µg/mL without S-9 and up to 437.5 µg/mL with S-9 and the following concentrations were selected for analysis:
4(20)-hour without S9: 0, 250, 312.5, 375 and 500 μg/mL
4(20)-hour with S9 (2%): 0, 125, 250 and 312.5 μg/mL
24-hour without S9: 0, 7.81, 15.63, 31.25 and 62.5 μg/mL
Proportion of cells with structural aberrations in negative control cultures fell within historical vehicle control ranges. Positive controls (Mitomycin C at 0.4 and 0.1 µg/mL without S-9 and cyclophosphamide at 2 µg/mL with S-9) induced the appropriate response. Treatment of cells with FRET 15-0735 in the presence or absence of S-9 in both experiments resulted in frequencies of cells with structural or numerical aberrations that were generally similar to those observed in concurrent vehicle controls for all concentrations analysed. Numbers of aberrant cells (excluding gaps) in treated cultures fell within the normal range.
Under the test conditions, FRET 15 -0735 is not considered as clastogenic in human lymphocytes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.